4
1
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T36558 |
(±)9-HETE
|
||
(±)9-HETE is one of the six monohydroxy fatty acids produced by the non-enzymatic oxidation of arachidonic acid. The individual R and S isomers of racemic HETEs have been separated and identified using chiral phase HPLC. The racemic HETEs have been quantified as an index of lipid peroxidation using GC/MS. | |||
T37411 |
9(S)-HETE
|
||
9(S)-HETE is an enantiomer which makes up 50% of (±)9-HETE . There are no reports of 9(S)-HETE occurring as an enzymatic lipoxygenation product. Whereas 12(S)-HETE promotes adhesion of several cell lines to endothelial cell monolayes, 9(S)-HETE and other positional HETEs are without effect. Stereochemical assignment of the (S) enantiomer is based on comparison of chiral HPLC retention times to published results. | |||
T37410 |
9(R)-HETE
|
||
9(R)-HETE is an enantiomer which makes up 50% of (±)9-HETE . At a concentration of 300 nM, 9(R)-HETE activates RXRγ-dependent transcription 1.5 fold relative to a control. Stereochemical assignment of the (R) enantiomer is based on comparison of chiral HPLC retention times to published results. | |||
T36462 |
CAY10770
CAY10770 |
||
CAY10770 is an inhibitor of the cytochrome P450 (CYP) isoform CYP4Z1 (IC50= 5.9 μM).1It is selective for CYP4Z1 over CYP4A11, CYP4F2, CYP4F3a, CYP4F3b (IC50s = 187-282 μM) but does inhibit CYP4F8 and CYP4F12 (IC50s = 167 and 91 μM, respectively). CAY10770 (3 μM) inhibits the production of 14(15)-EET, 19-HETE, and 14(15)-DiHET by 83, 86, and 80%, respectively, in T47D breast cancer cells expressing CYP4Z1. 1.Kowalski, J.P., McDonald, M.G., Pelletier, R.D., et al.Design and characterization of the... |
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T4740 |
Elaidic acid
反油酸,trans-Oleic Acid |
Endogenous Metabolite | Metabolism |
Elaidic acid (trans-Oleic Acid) 是在氢化植物油中发现的主要反式脂肪,能够被用作药物溶剂。在与花生四烯酸孵育的人类血小板中,反油酸抑制 HHT 和 HETE 的形成,同时诱导前列腺素和血栓素的合成。 |